Vericel Corporation 10-Q Summary
Business Context and Reporting Period
Vericel is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine and severe burn care. Its U.S. products are MACI, Epicel, and NexoBrid. This unaudited Form 10-Q covers the quarter ended March 31, 2023, with comparison to the quarter ended March 31, 2022.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $41.0 million | $36.1 million | 13.7% increase |
| Gross profit | $26.5 million | $23.5 million | 13.1% increase |
| Gross margin | 64.7% | 65.0% | Down approximately 30 bps |
| Operating loss | $8.2 million | $7.3 million | Loss increased $0.9 million |
| Net loss | $7.5 million | $7.1 million | Loss increased $0.4 million |
| Net loss per share | $0.16 | $0.15 | Loss per share increased |
| Operating cash flow | $7.9 million | $3.5 million | Increase of $4.4 million |
MACI revenue was $34.2 million, up 31.5%, driven by volume and price growth. Epicel revenue was $6.8 million, down 30.7%, reflecting lower volume. NexoBrid revenue was zero compared with $0.2 million in the prior-year quarter because the initial BARDA procurement was completed in the third quarter of 2022.
Research and development expense increased 7.2% to $5.2 million, while selling, general and administrative expense increased 14.0% to $29.5 million due primarily to higher headcount, employee expenses, travel, events, and marketing. Total other income increased to $0.7 million, principally because of higher interest income.
At March 31, 2023, Vericel had $61.8 million of cash and cash equivalents and $77.4 million of investments, for total cash and investments of approximately $139.2 million. Current assets were $177.5 million and current liabilities were $28.8 million. The company had no outstanding borrowings under its $150.0 million senior secured revolving credit facility, although approximately $6.2 million of the letter-of-credit sub-facility was utilized. Total operating lease liabilities were $46.9 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased $4.9 million, primarily from a $8.2 million increase in MACI revenue, partially offset by lower Epicel revenue and the absence of NexoBrid BARDA revenue.
- Gross profit increased, but gross margin declined modestly because of higher employee costs, raw-material prices, and external storage and manufacturing facility costs.
- Operating expenses increased $4.0 million, exceeding the $3.1 million increase in gross profit and producing a larger operating loss.
- Operating cash flow improved to $7.9 million, supported by collections of accounts receivable and noncash stock-based compensation of $8.7 million.
- The company paid a $7.5 million regulatory milestone to MediWound following FDA approval of NexoBrid; the payment was capitalized as an intangible asset.
- Stock-based compensation declined to $8.7 million from $9.5 million.
Guidance, Outlook, Risks, and Unusual Items
Management expects to receive commercial NexoBrid from MediWound and begin U.S. commercial sales during the third quarter of 2023, subject to MediWound completing manufacturing updates required by the FDA. NexoBrid commercial launch activities, including education, training, customer engagement, and deployment of additional account managers, were underway.
Management expects cash from product sales, existing cash, investments, and available borrowing capacity to support current operations for at least 12 months from issuance of the financial statements. The company remains loss-making, with an accumulated deficit of $407.5 million, and may require additional capital if revenue declines for a sustained period.
Vericel is expanding its Burlington, Massachusetts headquarters and manufacturing facility. In April 2023, it funded approximately $28.3 million, representing 50% of its required tenant-improvement contribution, into a construction escrow account and expects to fund the remainder in late 2023 or early 2024. The company also expects additional investment in specialized manufacturing and laboratory equipment. The Burlington lease is expected to involve monthly contractual payments of approximately $0.6 million to $0.8 million once rent obligations commence.
Key risks include dependence on MACI growth and elective surgical volumes, variability in Epicel demand, payer reimbursement and collectability estimates, FDA and regulatory requirements, MediWound’s ability to manufacture and supply NexoBrid, supply-chain disruption, execution of the Burlington facility expansion, financial institution liquidity risk, inflation, interest rates, geopolitical conditions, and any resurgence of COVID-19. A 50-basis-point change in the estimated uncollectible percentage for MACI receivables could change quarterly revenue by approximately $0.3 million.
The filing reports no material ongoing litigation, no material changes to previously disclosed risk factors other than financial-institution liquidity risks, and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of March 31, 2023.
Important Facts for Investors to Verify
- Whether NexoBrid commercial sales actually began in the third quarter of 2023 and the pace of market adoption.
- MACI volume growth, payer reimbursement trends, accounts-receivable collection experience, and the sustainability of MACI gross margins.
- The timing, total cost, and funding requirements for the Burlington facility and related manufacturing equipment.
- Cash burn, operating-loss trends, and whether additional equity or debt financing becomes necessary.
- MediWound’s manufacturing readiness, supply reliability, and exposure to international and raw-material supply chains.
- Potential future NexoBrid sales milestone payments of up to $125.0 million and tiered royalties on net sales.
- The effect of quarterly seasonality, severe-burn case variability, and any renewed disruption to elective procedures.